重大事件即時報告 8-K 2026-07-20

戴纳基Dyne Therapeutics旗下DMD藥物z-rostudirsen獲FDA優先審查，PDUFA日期定於2027年1月21日

AI 繁中摘要

📄 **申報類型：8-K（重大事件報告）**  
📅 **報告日期：2026年7月20日**  

**事件重點**  
Dyne Therapeutics 宣佈，美國 FDA 已正式受理其為治療適合外顯子 51 跳躍的杜氏肌肉營養不良症（DMD）患者而開發的藥物 **zeleciment rostudirsen（z-rostudirsen，亦稱 DYNE-251）** 所提交的 BLA（生物製品許可申請）。FDA 同時授予此 BLA **優先審查**資格，並設定《處方藥使用者付費法案》（PDUFA）目標行動日期為 **2027年1月21日**。  

**管理層展望**  
公司表示，若一切按預期時程推進，有望在 **2027年第一季度** 於美國市場正式推出 z-rostudirsen。該藥物被視為 DMD 治療領域的潛在突破，FDA 優先審查亦反映其未滿足醫療需求的重要性。  

**對投資者的潛在影響**  
- **正面催化劑**：BLA 獲優先審查並設定明確 PDUFA 日期，降低審批不確定性；若成功獲批，將為 Dyne 帶來首個商業化產品，並驗證其 FORCE™ 平台技術。  
- **風險提示**：FDA 可能要求補充數據或延遲審批；臨床試驗結果、監管溝通及商業化能力仍存不確定性。公司提醒投資者注意前瞻性陳述的風險，包括臨床試驗結果、資金充足性及監管審批結果等，詳情可參考其 SEC 申報文件。  

**總結** 🏥✨  
Dyne 的核心管線產品 z-rostudirsen 進入 FDA 優先審查階段，目標決限期為 2027 年 1 月 21 日。若成功獲批，將有望於 2027 年首季在美上市，為 DMD 患者提供新選擇，並為公司帶來里程碑式商業化突破。投資者應密切關注未來數月的監管動態及臨床數據更新。

展開英文正文

8-K
 
 
 
 0001818794false00018187942026-07-202026-07-20

  

  
UNITED STATES 
SECURITIES AND EXCHANGE COMMISSION 
WASHINGTON, D.C. 20549 
 
FORM 8-K
 
CURRENT REPORT 
Pursuant to Section 13 or 15(d) 
of the Securities Exchange Act of 1934 
Date of report (Date of earliest event reported): July 20, 2026
 
Dyne Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter) 
 
 

 
 
 
 
 
 

 
 Delaware

 001-39509

 36-4883909

 

 
 (State or Other Jurisdiction
of Incorporation)

 (Commission
File Number)

 (IRS Employer
Identification No.)

 

 
  

  

  

 

 
 1560 Trapelo Road
Waltham, Massachusetts

  

 02451

 

 
 (Address of Principal Executive Offices)

  

 (Zip Code)

 

  
Registrant’s telephone number, including area code: (781) 786-8230
Not applicable 
(Former Name or Former Address, if Changed Since Last Report) 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): 
 

 
 
 
 
 

 
 ☐

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

 

 

 
 
 
 
 

 
 ☐

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

 

 

 
 
 
 
 

 
 ☐

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

 

 

 
 
 
 
 

 
 ☐

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

 

 Securities registered pursuant to Section 12(b) of the Act: 
 

 
 
 
 
 
 
 
 

 
 Title of each class

 

 Trading symbol(s)

 

 Name of each exchange on which registered

 

 
 Common stock, $0.0001 par value per share

 

 DYN

 

 Nasdaq Global Select Market

 

  
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 
Emerging growth company ☐ 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 
 

  

 
  

 Item 8.01 Other Events.
On July 20, 2026, Dyne Therapeutics, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review its biologics license application (“BLA”) for zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) for the treatment of individuals with Duchenne muscular dystrophy (“DMD”) amenable to exon 51 skipping. The FDA has granted the BLA Priority Review and assigned a Prescription Drug User Fee Act target action date of January 21, 2027. The Company continues to expect a potential U.S. launch of z-rostudirsen in the first quarter of 2027, assuming approval is received on the anticipated timeline.
 
Cautionary Note Regarding Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Current Report on Form 8-K, including statements regarding the Company’s strategy, future operations, prospects and plans, objectives of management, the potential of the FORCETM platform, the clinical and therapeutic potential of z-rostudirsen, the potential of z-rostudirsen to advance the treatment paradigm in Duchenne muscular dystrophy, expectations regarding the timing and outcome of interactions with regulatory authorities and the timing of regulatory authority action, and expectations regarding the timing of commercialization of z-rostudirsen, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” “will,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the initiation and completion of preclinical studies and clinical trials; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; uncertainties as to the FDA’s and other regulatory authorities’ interpretation of the data from the Company’s clinical trials and the regulatory approval process; whether the Company’s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; as well as the risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s most recent Form 10-Q and in subsequent filings the Company may make with the SEC. In addition, the forward-looking statements included in this Current Report on Form 8-K represent the Company’s views as of the date of this Current Report. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.
 

  

 
  

 SIGNATURES 
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 
 

 
 
 
 
 
 
 
 
 
 

 
  

  

  

  

  

  

  

 

 
  

 

 DYNE THERAPEUTICS, INC.

 

 
  

  

  

 

 
 Date: July 20, 2026

 

 By:

 

 /s/ John G. Cox

 

 
  

 

  

 

 Name:

 

 John G. Cox

 

 
  

 

  

 

 Title:

 

 President and Chief Executive Officer